Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

1.

Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.

[No authors listed]

Ann Neurol. 1997 Nov;42(5):747-55. Erratum in: Ann Neurol 1998 Aug;44(2):292.

PMID:
9392574
[PubMed - indexed for MEDLINE]
2.

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.

Brooks DJ, Sagar H; UK-Irish Entacapone Study Group.

J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071-9.

PMID:
12876237
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E; LARGO study group.

Lancet. 2005 Mar 12-18;365(9463):947-54.

PMID:
15766996
[PubMed - indexed for MEDLINE]
4.

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M; Celomen Study Group.

Acta Neurol Scand. 2002 Apr;105(4):245-55.

PMID:
11939936
[PubMed - indexed for MEDLINE]
5.

Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.

Fung VS, Herawati L, Wan Y; Movement Disorder Society of Australia Clinical Research and Trials Group; QUEST-AP Study Group.

Mov Disord. 2009 Jan 15;24(1):25-31. doi: 10.1002/mds.21878.

PMID:
18846551
[PubMed - indexed for MEDLINE]
6.

Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.

Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix I; F-01 Study Group.

Eur Neurol. 2001;45(2):111-8.

PMID:
11244274
[PubMed - indexed for MEDLINE]
7.

Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.

Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow CW, Ruzicka E, Bibbiani F, Squillacote D, Patten A, Tolosa E.

Clin Neuropharmacol. 2012 Jan-Feb;35(1):15-20. doi: 10.1097/WNF.0b013e318241520b.

PMID:
22222634
[PubMed - indexed for MEDLINE]
8.

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.

Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, Hubble J; US01 Study Team.

Arch Neurol. 2004 Oct;61(10):1563-8.

PMID:
15477510
[PubMed - indexed for MEDLINE]
9.

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group.

Rinne UK, Larsen JP, Siden A, Worm-Petersen J.

Neurology. 1998 Nov;51(5):1309-14.

PMID:
9818851
[PubMed - indexed for MEDLINE]
10.

Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease.

Brooks DJ, Leinonen M, Kuoppamäki M, Nissinen H.

J Neural Transm. 2008 Jun;115(6):843-9. doi: 10.1007/s00702-008-0025-8. Epub 2008 Feb 8.

PMID:
18259682
[PubMed - indexed for MEDLINE]
11.

Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.

Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K; ComQol Study Group.

Acta Neurol Scand. 2005 Jan;111(1):21-8.

PMID:
15595934
[PubMed - indexed for MEDLINE]
12.

Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.

Grandas F, Hernández B; PRACTICOMT Study Group.

Eur J Neurol. 2007 Mar;14(3):282-9.

PMID:
17355548
[PubMed - indexed for MEDLINE]
13.

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.

Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A.

J Neurol Neurosurg Psychiatry. 2000 May;68(5):589-94.

PMID:
10766888
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease.

Larsen JP, Worm-Petersen J, Sidén A, Gordin A, Reinikainen K, Leinonen M; NOMESAFE Study Group.

Eur J Neurol. 2003 Mar;10(2):137-46.

PMID:
12603288
[PubMed - indexed for MEDLINE]
16.

Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.

Najib J.

Clin Ther. 2001 Jun;23(6):802-32; discussion 771. Review.

PMID:
11440283
[PubMed - indexed for MEDLINE]
17.

[Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].

Kulisevsky J.

Neurologia. 1999 Aug-Sep;14(7):349-58. Review. Spanish.

PMID:
10570622
[PubMed - indexed for MEDLINE]
18.

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.

Ann Neurol. 2010 Jul;68(1):18-27. doi: 10.1002/ana.22060. Erratum in: Ann Neurol. 2010 Sep;68(3):412-3.

PMID:
20582993
[PubMed - indexed for MEDLINE]
19.

Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort.

Damier P, Viallet F, Ziegler M, Bourdeix I, Rerat K.

Eur J Neurol. 2008 Jul;15(7):643-8. doi: 10.1111/j.1468-1331.2008.02165.x.

PMID:
18582341
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk